Driving research of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS),
Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia and Long Covid

Three new groundbreaking research projects!

#TripleGivingTuesday Research Feature

A conversation with Dr. Alain Moreau: Three groundbreaking research projects underway! 🔬

It’s the third week of #TripleGivingTuesday, OMF’s largest fundraising campaign of the year! When you give to OMF between now and November 30, your gift is TRIPLE matched — that’s triple the research impact!

In honor of the campaign, we are pleased to share with you a new interview with Alain Moreau, Director of the OMF established ME/CFS Collaborative Research Center at the CHU Sainte-Justine/ Université de Montréal. Recently, Dr. Moreau discussed with us three groundbreaking projects underway at the Collaborative Center at Montréal!

How did you first enter the field of ME/CFS research?

In 2015, I was the Director of Research and Chief Scientific Officer at CHU Sainte-Justine University Hospital in Montreal. A friend (Dr. Morris Duhaime) requested my advice about the research priorities in the field of ME/CFS, how to increase research capacity, and what should be done to accelerate the discovery of biomarkers and treatments.

Per his request, I submitted my scientific report regarding the current state-of-the-art in the field of ME/CFS. I found the limited knowledge available for a disease affecting millions of people worldwide very troublesome. After that, I suggested a research proposal to a private foundation, which was accepted and funded.

What was most surprising to you when first learning about this disease?

ME/CFS is probably the last 21st-century medical enigma affecting millions worldwide. Despite such a high incidence and the alarming rise of affected people, only a few groups of researchers were investigating this complex chronic disease. Furthermore, because ME/CFS is an orphan disease (a common condition that has been ignored) due to the historical lack of recognition as a real physical disease, there has been a delay in researching and developing innovative treatments.

Can you give us a bit of a background on the projects you’re working on now?

Currently, we are working on three research projects:

    • MAESTRO-ME (Multi-omic Approaches to Resolve Myalgic Encephalomyelitis)

    • SCOPIMED (Study of COVID- 19 survivors’ Profiles for detection of Myalgic Encephalomyelitis Development)

    • DOMINO-ME (Deep proteome and Metabolome profiling to decode Myalgic Encephalomyelitis)

MAESTRO-ME: The overarching goal of this project is to identify biomarkers (in plasma and urine) for the diagnosis of ME/CFS, classify patients in subgroups associated with symptom severity, and predict their therapeutic response to drugs that can be repurposed to treat ME/CFS.

We have so far uncovered 11 different microRNAs associated with ME/CFS that can differentiate ME/CFS patients from healthy patients with 90 percent accuracy!

Secondly, we identified additional circulating proteins (for instance, thrombospondin-1) associated with specific symptoms (POTS, brain fog, fatigue, etc.) that could be targeted by drugs currently used to treat other diseases.

SCOPIMED: The goal of this research proposal is to understand the molecular mechanisms underlying the development of persistent symptoms following COVID-19 infection in non-hospitalized patients. Recent estimates suggest that around 30 percent of non-hospitalized patients will develop Long COVID. Our research team is well-positioned to provide a comprehensive understanding as to why some COVID-19 survivors develop ME/CFS and related chronic conditions (e.g., FM) while others do not.

ME/CFS researchers understand that viral infections, combined with other factors, likely contribute to the onset of ME/CFS and related conditions. However, it is also essential to identify the molecular mechanisms leading to the development of these conditions.

Additionally, this project aims to distinguish ME/CFS symptoms from other types of symptoms in people with Long-COVID,  as early as possible. Such an approach can lead to the evolution of algorithms predicting their clinical trajectories. It also offers an opportunity to identify targeted treatment strategies.

DOMINO-ME: The goal of this project is to better understand the molecular mechanisms underlying ME/CFS pathophysiology and the variability of the symptoms. Ultimately, this can lead to the identification of treatment targets and intervention strategies.

The DOMINO-ME project will expand on our deep phenotyping characterization of ME/CFS patients, (the process of visualizing how the molecular mechanisms underlying ME/CFS present themselves), developed during the MAESTRO-ME project. By combining proteomics and metabolomics plasma sample profiling, we hope to discover strategies to uncover the process in which ME/CFS develops.

DOMINO-ME mobilizes three OMF Collaborative ME/CFS Research Centers (Melbourne, Montreal, and Uppsala) and is a good example of what can be achieved when multidisciplinary research teams collaborate. 

It is amazing news that your team has so far uncovered 11 different microRNAs associated with ME/CFS that are capable of differentiating ME/CFS patients from healthy patients with 90 percent accuracy.  What is the significance of this finding, and what do you hope will come of it?

These microRNA differential expression signatures can discriminate ME/CFS subjects from healthy controls and can potentially be a tool for predicting therapeutic responses with machine learning algorithms. This new diagnostic microRNA panel is now used for the SCOPIMED project to confirm the diagnosis of ME/CFS among individuals suffering from Long-COVID.

 What else are you hoping to learn from your current research projects?

Besides developing and validating new diagnostic/prognostic biomarkers and clinical tools, we hope to soon confirm therapeutic targets that can be treated by drugs currently used for other conditions.

What gives you the most hope for the future of ME/CFS research and patients? 

Open Medicine Foundation has created a unique collaborative research ecosystem that is certainly a game-changer in the field of ME/CFS. By promoting excellence in research and sustaining collaboration between different centers and investigators, OMF brings us closer to a cure for ME/CFS. It takes time and multiple investments to arrive at trailblazing discoveries, and I am sure that we are at the brink of achieving that in the near future.

See a word you don’t understand? 

Want to deepen your understanding of what we’re researching? 

Check out our Research Definitions and Terminology page!

Join us in this outstanding effort to uncover answers as we boldly move closer to the discovery of a diagnostic test, treatments, and a cure for ME/CFS and related multisystem chronic, complex diseases. All donations to OMF will be TRIPLED from now until November 30, giving you the exciting opportunity to triple  your support of this innovative research.

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

What are the advantages of giving from your Donor Advised Fund (DAF)?

  • Your gifts to your donor advised fund entitle you to an immediate income tax deduction at the time of contribution.
  • You avoid capital gains tax on appreciated assets you place in your donor advised fund.
  • Your fund’s investment gains accumulate tax free.
  • Funds are distributed to Open Medicine Foundation in your name and immediately put to use to support our worldwide research efforts.

How do I make a donation through my DAF?

Just click on the DAF widget below. It is simple and convenient to find your fund among the over 900 funds in our system.

Still can’t find your fund? 

  • Request a grant distribution through your Donor Advised Fund sponsor
  • Be sure to use OMF’s EIN #26-4712664
  • You can also designate OMF as a beneficiary for your Donor Advised Fund
  • Questions? Give us a call at 650-242-8669 
 

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

Averting a second pandemic:

Open Medicine Foundation leads groundbreaking international study of

Long COVID’s conversion to ME/CFS

AGOURA HILLS, CALIF.  — Open Medicine Foundation (OMF) is leading a large-scale international collaborative study investigating the potential conversion of Post-Acute Sequelae SARS-CoV-2 infection — more commonly known as Long COVID or Post-COVID Syndrome —  to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a chronic, life-altering disease with no known cause, diagnostic test or FDA approved treatments available.

Up to 2.5 million people in the U.S. alone suffer from ME/CFS; the COVID-19 pandemic could at least double that number. An estimated 35 percent of Americans who had COVID-19 have failed to fully recover several months after infection, prompting many to call it “a potential second pandemic.”

OMF recognized a familiar health crisis emerging, one with eerie similarities to ME/CFS. This crisis presented a unique opportunity to understand how a viral infection — in this case COVID-19 — may develop into ME/CFS in some patients. The goal is to find targeted treatments for ME/CFS patients and ultimately prevent its onset in people infected with SARS-CoV-2 or other infections.

The federal government is only now investing in Post-COVID research, with no focus on its connection to ME/CFS. OMF has already engaged researchers for the largest-scale study of its kind, solely supported by private donors who have contributed over one million dollars to date. When fully funded, the five million dollar, three-year study will be conducted across the globe at OMF funded Collaborative Research Centers, led by some of the world’s top researchers and ME/CFS experts.

BACKGROUND

In a significant percentage of patients, infections preceded their development of ME/CFS.  For example, according to the CDC about one in ten infected with Epstein-Barr virus, Ross River virus, or Coxiella burnetti develop symptoms that meet the criteria for ME/CFS.

THE STUDY

The ability to follow the development of ME/CFS from a known viral infection is unprecedented to date and crucial to researchers’ understanding of the disease. The focus of this study is to find the biological differences between persons returning to good health after COVID-19 and persons who remained ill more than six months after infection and developed ME/CFS.  Understanding these alterations in key pathways can lead to groundbreaking discoveries including new biomarkers, drug targets, and prevention and treatment strategies.

###

About Open Medicine Foundation

Established in 2012, Open Medicine Foundation leads the largest, concerted worldwide nonprofit effort to diagnose, treat, and prevent ME/CFS and related chronic, complex diseases such as Post Treatment Lyme Disease Syndrome, Fibromyalgia, and Post COVID. OMF adds urgency to the search for answers by driving transformational philanthropy into global research. We have raised over $28 Million from private donors and facilitated and funded the establishment of six prestigious ME/CFS Collaborative Research Centers around the world. To learn more, visit www.omf.ngo.

CONTACT:

Heather Ah San

Development and Communications Manager

1-650-242-8669

heather@omf.ngo